|
![]() |
貨號(hào) | 品名 | 規(guī)格 | 包裝 | 單價(jià) | 貨期 | 庫(kù)存 |
JD200512101506 | Obinutuzumab | -- | 5mg | 16200元 | 咨詢客服 | 3天 |
JD200512101456 | Obinutuzumab | -- | 1mg | 6600元 | 咨詢客服 | 3天 |
性狀: | Obinutuzumab (GA101) 是新型糖工程化II型CD20單克隆抗體,開發(fā)用來(lái)治療非霍奇金淋巴瘤。 |
質(zhì)量標(biāo)準(zhǔn): | Description Obinutuzumab (GA101) a novel glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma. Shipping Shipping with dry ice. Storage Please store the product under the recommended conditions in the Certificate of Analysis. References [1]. Herter S, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013 Oct;12(10):2031-42. [2]. Dalle S, et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody -GA101. Mol Cancer Ther. 2011 Jan;10(1):178-85. [3]. Herting F, et al. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab(GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leuk Lymphoma. 2014 Sep;55(9):2151-5160. |